Dr. Alkhouri is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
607 Camden St
Ste 108
San Antonio, TX 78215Phone+1 210-253-3426Fax+1 210-237-4807
Education & Training
- Cleveland Clinic FoundationFellowship, Pediatric Gastroenterology, 2007 - 2010
- Albert Einstein Medical CenterResidency, Internal Medicine/Pediatrics, 2003 - 2007
- Damascus University Faculty of MedicineClass of 2001
Certifications & Licensure
- AZ State Medical License 2020 - 2026
- OH State Medical License 2007 - 2025
- TX State Medical License 2017 - 2025
- PA State Medical License 2003 - 2007
- American Board of Internal Medicine Internal Medicine
- American Board of Obesity Medicine Obesity Medicine
Clinical Trials
- Mediterranean Diet and Protein-Sparing Modified Diet for Metabolic Syndrome in Liver Transplant Recipients Start of enrollment: 2014 Jun 01
Publications & Presentations
PubMed
- Design and rationale for a global novel non-invasive screening observational study using genetics and non-invasive methodologies to identify at-risk MASLD participants...Samuel J Daniels, Karin Nelander, John Eriksson, Lutz Jermutus, Jelena Saillard
Contemporary Clinical Trials Communications. 2025-04-01 - 1 citationsDecreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH.Naim Alkhouri, Cayden Beyer, Elizabeth Shumbayawonda, Anneli Andersson, Kitty Yale
Journal of Hepatology. 2025-03-01 - A phase IIb randomised-controlled trial of the FFAR1/FFAR4 agonist icosabutate in MASH.Stephen A Harrison, Naim Alkhouri, Grisell Ortiz-Lasanta, Madhavi Rudraraju, Dean Tai
Journal of Hepatology. 2025-02-10
Journal Articles
- NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications for Liver Transplant and Ethnic and Gender VariancesTsuyoshi Todo, Walid S Ayoub, Naim Alkhouri, Nicholas N Nissen, Vinay Sundaram, Shelly C Lu, Mazen Noureddin, Aarshi Vipani, Tram Tran, Andrew S Klein, Nature
Press Mentions
- PharmaIN Unveils Interim Phase 1b Clinical Data on the Activity and Safety of PHIN-214 in Decompensated Liver Cirrhosis at AASLD - the Liver Meeting® 2024November 18th, 2024
- 89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD the Liver Meeting® 2024November 15th, 2024
- MRI Biomarkers Identify Histologic Improvement in MASHNovember 8th, 2024
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: